Skip to main content

Table 1 Baseline characteristics

From: Comprehensive analysis of coagulation indices for predicting survival in patients with biliary tract cancer

Characteristics Entire cohort Training cohort Validation cohort P
Age (year) 62 (23–89) 62 (35–89) 63 (23–88) 0.120
Sex     0.947
 Female 208 (46.2%) 139 (46.3%) 69 (46.0%)  
 Male 242 (53.8%) 161 (53.7%) 81 (54.0%)  
Malignancy type     0.984
 ICC 99 (22.0%) 65 (21.7%) 34 (22.7%)  
 ECC 225 (50.0%) 152 (50.7%) 73 (48.7%)  
 GBC 126 (28.0%) 83 (27.6%) 43 (28.6%)  
Tumor differentiation [425] [286] [139] 0.521
 Poor 162 (38.1%) 106 (37.1%) 56 (40.3%)  
 Modest-well 263 (61.9%) 180 (62.9%) 83 (59.7%)  
Tumor size (cm) 2.5 (0.2–18.0) 2.5 (0.2–18.0) 2.2 (2.0—13.0) 0.751
TNM stage     0.619
 I 141 (31.3%) 100 (33.3%) 41 (27.3%)  
 II 131 (29.1%) 84 (28.0%) 47 (31.3%)  
 III 127 (28.2%) 82 (27.3%) 45 (30.00%)  
 IV 51 (11.4%) 34 (11.4%) 17 (11.4%)  
Curative surgery [447] [297]   0.511
 No 190 (42.5%) 123 (41.4%) 67 (44.7%)  
 Yes 257 (57.5%) 174 (58.6%) 83 (55.3%)  
Jaundice     0.423
 No 210 (46.7%) 136 (45.3%) 74 (49.3%)  
 Yes 240 (53.3%) 164 (54.7%) 76 (50.7%)  
Diabetes     0.239
 No 362 (84.4%) 246 (82.0%) 116 (77.3%)  
 Yes 88 (19.6%) 54 (18.0%) 34 (22.7%)  
Hypertension     0.070
 No 314 (69.8%) 201 (67.0%) 113 (75.3%)  
 Yes 136 (30.2%) 99 (33.0%) 37 (24.7%)  
Fatty liver     0.168
 No 422 (93.8%) 278 (92.7%) 144 (96.0%)  
 Yes 28 (6.2%) 22 (7.3%) 6 (4.0%)  
Liver cirrhosis     0.265
 No 435 (96.7%) 288 (96.0%) 147 (98.0%)  
 Yes 15 (3.3%) 12 (4.0%) 3 (2.0%)  
FBG (g/L) 3.765 (1.53–13.00) 3.74 (1.53–13.00) 3.77 (1.61–12.50) 0.566
PT (s) 11.7 (2.4–18.3) 11.7 (2.4–18.3) 11.7 (9.7–18.2) 0.288
PTA (%) 91.25 (43.5–126.4) 91.7 (43.5–126.4) 90.4 (49.8–116.6) 0.220
INR 1.00 (0.75–3.71) 0.995 (0.75–3.71) 1.01 (0.80–1.92) 0.148
APTT (s) 26.4 (17.2–51.3) 26.45 (17.2–51.3) 26.35 (19.1–48.1) 0.957
APTT-R 0.98 (0.63–2.75) 0.98 (0.63–2.75) 0.975 (0.71–1.77) 0.816
TT (s) 18.0 (10.2–24.4) 18.1 (10.2–24.4) 17.8 (14.2–22.5) 0.136
PLT (×109/L) 227 (76–773) 228.5 (92–773) 224 (76–506) 0.736
CA19–9 (U/mL) [438] [290] [148] 0.840
 ≤ 37 124 (28.3%) 83 (28.6%) 41 (27.7%)  
 > 37 314 (71.7%) 207 (71.4%) 107 (72.3%)  
ALT (U/L)     0.539
 ≤ 40 177 (39.3%) 121 (40.3%) 56 (37.3%)  
 > 40 273 (60.7%) 179 (59.7%) 94 (62.7%)  
AST (U/L) [429] [290] [139] 0.192
 ≤ 40 186 (43.4%) 132 (45.5%) 54 (38.8%)  
 > 40 243 (56.6%) 158 (54.5%) 85 (61.2%)  
GGT (U/L) [432] [293] [139] 0.872
 ≤ 40 82 (19.0%) 55 (18.8%) 27 (19.4%)  
 > 40 350 (81.0%) 238 (81.2%) 112 (80.6%)  
ALB (g/L) [448] [299] [149] 0.725
 ≤ 35 89 (19.9%) 58 (19.4%) 31 (20.8%)  
 > 35 359 (80.1%) 241 (80.6%) 118 (79.2%)  
Blood loss during surgery (mL) 300 (0–8000) 300 (0–8000) 300 (0–4000) 0.820
Postoperative hospitalization (day) 14 (1–155) 14 (1–155) 12 (2–91) 0.294
Postoperative complication     0.447
 No 284 193 91  
 Yes 166 107 59  
  1. P-values in the last column belong to the training and validation cohorts. Asterisks indicate P-values of statistical significance. Continuous variables were shown as medians and ranges, and categorical variables were reported as numbers and percentages. For variables with missing data, the numbers of available cases were shown in square brackets